Related Experiment Video
Updated: Dec 9, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
Associations Between Depressive Symptoms and HFpEF-Related Outcomes
Alvin Chandra1, Michael A D Alcala2, Brian Claggett3
1Cardiology Division, University of Texas Southwestern, Dallas, Texas, USA.
Insights
Higher baseline depressive symptoms in heart failure patients predict mortality. Worsening symptoms also increase mortality risk, while spironolactone may offer some improvement.
Area of Science:
- Cardiology
- Psychiatry
- Clinical Trials
Background:
- Limited longitudinal data exist on depressive symptoms in heart failure with preserved ejection fraction (HFpEF).
- Depression is a significant comorbidity in cardiovascular disease, impacting patient outcomes.
Purpose of the Study:
- To analyze changes in depressive symptoms in HFpEF patients within the TOPCAT trial.
- To identify predictors of depressive symptom changes and their impact on cardiovascular events and mortality.
Main Methods:
- 1,431 patients from the US and Canada in the TOPCAT trial had depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9).
- Clinically meaningful changes were defined as a ≥3-point increase (worse) or decrease (better).
- Multivariate and Cox proportional hazard models were used to analyze predictors and outcomes.
Main Results:
- At 12 months, 19% of patients had worsening symptoms, 31% improved, and 49% remained unchanged.
- Higher baseline PHQ-9, male sex, no COPD, and spironolactone randomization predicted improvement.
- Higher baseline PHQ-9 predicted all-cause mortality (HR 1.09). Worsening symptoms predicted cardiovascular death (HR 2.47) and all-cause mortality (HR 1.82).
- Spironolactone was associated with a modest reduction in depressive symptoms (p=0.014).
Conclusions:
- Elevated baseline and worsening depressive symptoms are linked to increased all-cause mortality in HFpEF patients.
- Randomization to spironolactone showed a modest but significant association with reduced depressive symptoms.
Objectives:
This study analyzed changes in depressive symptoms in patients with heart failure and preserved ejection fraction (HFpEF) who were enrolled in the TOPCAT (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function) trial.
Background:
There are limited longitudinal data for depressive symptoms in patients with HFpEF.
Methods:
In patients enrolled in the United States and Canada (n = 1,431), depressive symptoms were measured using Patient Health Questionnaire-9 (PHQ-9). Clinically meaningful changes in PHQ-9 scores were defined as worse (≥3-point increase) or better (≥3-point decrease). Multivariate models were used to identify predictors of change in depressive symptoms. Cox proportional hazard models were used to determine the impact of symptom changes from baseline on subsequent incident cardiovascular events.
Results:
At 12 months, 19% of patients experienced clinically worsening depressive symptoms, 31% better, and 49% unchanged. Independent predictors of clinically meaningful improvement in depressive symptoms included higher baseline PHQ-9 scores, male sex, lack of chronic obstructive pulmonary disease, and randomization to spironolactone. After data were adjusted for cardiovascular comorbidities, higher baseline PHQ-9 was associated with all-cause mortality (hazard ratio [HR]: 1.09; 95% confidence interval [CI]: 1.02 to 1.16; p = 0.011), whereas worsening depressive symptoms at 12 months were associated with cardiovascular death (HR: 2.47; 95% CI: 1.32 to 4.63; p = 0.005) and all-cause mortality (HR: 1.82; 95% CI: 1.13 to 2.93; p = 0.014). Randomization to spironolactone was associated with modest but statistically significant reduction in depressive symptoms over the course of the trial (p = 0.014).
Conclusions:
Higher baseline depressive symptoms and worsening depressive symptoms were associated with all-cause mortality. Randomization to spironolactone was associated with modest reduction in depressive symptoms. (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function [TOPCAT]; NCT00094302).
More Related Videos
Related Concept Videos
Pathophysiology of Heart Failure
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Depressive Disorders: MDD and Dysthymia
Self-Discrepancy and Its Effects
Heart Failure I: Introduction
Depression: Overview

